Background Aim was to assess the long-term clinical efficacy of infliximab therapy in Crohn's disease patients treated in a cohort of two tertiary referral centers in the Netherlands.
Introduction
Crohn's disease (CD) is a chronic inflammatory disease affecting the entire gastrointestinal tract. The disease is clinically characterized by frequent relapses despite intensive medical and surgical therapy. 1 These frequent relapses impair quality of life of CD patients and lead to high health care costs. [2] [3] [4] The introduction of biological therapy some 17 years ago, targeting specific inflammatory cytokines, caused a revolutionary shift in treatment options. 5 The first biological agent available for treatment of CD was infliximab (IFX), a monoclonal chimeric antibody directed against the inflammatory cytokine tumour necrosis factor (TNF). 6 By supposedly neutralizing both membrane-bound and free TNF, CD-associated inflammatory activity is scaled down dramatically. The discovery of IFX signified a major milestone in CD therapy since its success unlocked a new clue for a large set of new compounds targeting single proteins involved in the immune response. 5 In Europe, IFX is commercially available since 1999. In the years preceding approval, several large trials have shown its superiority compared to placebo in inducing and maintaining remission in luminal and fistulising CD. [7] [8] [9] [10] [11] However, a substantial number of patients is primary non-responder or develops antibodies that may lead to loss of response or to adverse effects such as infusion reactions. Two factors that can reduce antibody formation -immunosuppressive co-medication and a scheduled treatment regimen rather than a 'on demand' strategy -appear to improve therapeutic efficacy. [12] [13] [14] Yet, IFX therapy is not beneficial in all patients. Because of the chronic relapsing character of CD, often debuting at young age, long-term efficacy follow-up is of particular interest to assess sustained benefit and safety of therapy. Most clinical trials performed so far had a maximum follow-up of only 12 months. Moreover, the randomized clinical trials that provided most of the current published efficacy data suffer from selection bias, which complicates translation of results into daily practice. In addition, the main endpoint in all clinical trials was the Crohn's Disease Activity Index (CDAI), which does not necessarily mirror clinical efficacy as judged by global physician's assessment (GPA). Publications concerning daily practice data are scarce. The Academic Medical Center (AMC) and the Free University Medical Centre (VUMC) are both high volume tertiary referral centres in Amsterdam, the Netherlands, with a longstanding comprehensive experience in anti-TNF therapy for inflammatory bowel disease (IBD). As a matter of fact, the first CD patient ever to receive IFX was treated at the AMC in 1993. 15 Aim of the present study was to evaluate the long-term efficacy and safety of all consecutive CD patients who received IFX for Crohn's disease in the AMC or VUMC in the past decade.
Methods

Study population
This retrospective cohort study concerned all consecutive CD patients who started IFX since its first administration in 1993 to treat CD in the AMC or VUMC. The IBD databases were searched to identify all CD patients who were treated with IFX. Only CD patients with sufficient follow-up data to assess the endpoints were included in this analysis. The end of the study period was set on December 1 st 2009 for AMC patients and April 1 st 2010 for VUMC patients. If patients were referred to other hospitals or otherwise lost to follow-up, the date of the last contact with AMC or VUMC was considered the end of the follow-up period.
Data collection
All medical charts were retrospectively reviewed. Patient characteristics and circumstances at time of initiation of IFX treatment were assessed. Treatment schedule was defined as 'remission induction' if a maximum of three infusions were administered within a period of three months. Subsequent maintenance therapy was defined as 'episodic' if infusions were given only upon relapse of symptoms or 'scheduled' if therapy was given according to a regular scheme.
Endpoints and assessments
Primary endpoint of the study was sustained benefit of IFX treatment. Sustained benefit was defined as ongoing treatment in patients on maintenance therapy, and is regarded to parallel global physician's assessment of benefit. Discontinuation because of sustained remission, pregnancy or due to patients' request was also defined as benefit. These patients were censored at time of treatment discontinuation. Failure of maintenance therapy was defined as loss of response according to global physician's assessment or the occurrence of adverse events that led to discontinuation of treatment. Success of remission induction was assessed by global physician's assessment. Patients without sufficient response during the first three infusions were considered primary non-responders. Discontinuation of therapy within the first three infusions period because of an adverse event or co-morbidity was also considered failed remission induction. Factors possibly affecting remission induction, such as patient-and disease specific characteristics, were investigated by multivariate regression analyses. To rule out a hospital bias, the AMC-and VUMC-cohort were compared regarding the outcome of maintenance therapy.
Three secondary endpoints were investigated. First secondary endpoint was the incidence of surgical interventions. The number of abdominal surgical interventions for complicated CD per 100 follow-up years before and after start of IFX was compared. A sub-analysis was performed for the group of patients who received scheduled maintenance therapy, irrespective of eventual treatment failure or success. In addition, timing of surgery after the first administration was determined with stratification for treatment success and failure. Abdominal surgical interventions consisted of resections, faecal diversion, stricture plasties and intraabdominal abscess drainages.
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Another secondary endpoint was the success of re-treatment with IFX. Retreatment was defined as a new IFX therapy episode after discontinuation of previous IFX therapy. Treatment success was assessed as described above. The outcome of retreated patients who previously had discontinued treatment because of treatment failure was specifically addressed. Influence of additional therapies (resection, adalimumab or trial medication) between the first and second IFX episode, was assessed by means of univariate analysis. Analyses were performed for the retreated patient group as a whole and for the subgroup of patients who were retreated despite previous IFX failure.
Safety was the third secondary endpoint. An adverse event (AE) was defined as any reaction or side effect that occurred during the course of the treatment, regardless of whether the event was considered related to IFX therapy. Two categories were addressed in more detail: mortality and malignancy after initiation of treatment. The association of AE with IFX was judged by three independent experts (PS, CP and AvB) as 'not related', 'possibly related', 'probably related' or 'certainly related'.
Statistical analysis
Continuous variables are presented as means with the standard deviation (SD). In case of skewed data, medians with their interquartile range (IQR) are presented. For differences in proportions a Chi-Square test or Fisher's Exact test was used. Univariate and multivariate regression analyses were performed to assess factors predictive for failure of remission induction. Outcome hereof is presented as odds ratio (OR) with its 95% confidence interval (CI). Sustained benefit of IFX therapy was determined by Kaplan-Meier analysis. From this analysis, the estimated 5-year benefit was calculated. The Kaplan-Meier analysis was stratified for several factors. To test for differences in failure-free survival, the log-rank test was used. For comparison of the rates of abdominal surgical interventions pre-and post-IFX, the nonparametric bootstrap was applied. With this method, samples of the same size as the original data set were drawn by sampling with replacement from the observed data. A bootstrap with 1000 replications was performed to obtain distribution of surgical rate differences. From these bootstrapped distributions the 95% CI and P-values were calculated. A Kaplan-Meier analysis was performed to estimate resection-free survival after start of treatment. A P-value of < 0.05 was considered statistically significant. Statistical analyses were performed by using SPSS® software version 15.0 (SPSS Inc., Chicago, IL, USA). For the non-parametric bootstrap, statistical software from the R-project was used. 16 
Ethical considerations
The Medical Ethical Committee of the AMC approved the study.
Results
Patient characteristics
Since the introduction of IFX for CD, a total of 488 CD patients received IFX. From 19 patients, follow-up was insufficient to assess efficacy. From the remaining 469 (95.9%), 413 (84.6%) were still being treated at the AMC or VUMC. Median follow up was 4.5 years (IQR: 2.7 to 6.8) with a total of 2294 patient years. During the study period, a total of 8301 infusions were administered. Patient characteristics are depicted in Table 1 . Mean age at start of IFX was 33.3 years (SD: 12.1), after a median disease duration of 6.5 (IQR: 1.9 -13.3) years. Figure 1 shows the course of the primary treatment episode of all patients who received IFX. The first sub-division in the algorithm shows that 70 patients (15%) had an unsuccessful induction course. In univariate analysis, perforating CD behaviour (P = 0.04; OR: 1.860, 95% CI 1.020-3.392) and no concomitant thiopurine therapy (P = 0.004; OR: 2.194, 95% CI 1.285-3.747) were found to be significantly associated with failure of remission induction. Previous surgical resection showed a trend towards a positive association with therapy success (P = 0.070; OR: 0.624, 95% CI 0.375-1.040). In multivariate analysis, adjusting for confounding factors, the only factor associated with unsuccessful remission induction remained 'no concomitant thiopurine therapy' (P = 0.008; OR: 2.103, 95% CI 1.218-3.630).
Induction therapy
Sustained benefit
Of the 399 patients (85%) with successful induction course, 316 patients continued with maintenance therapy (Figure 1) . A successful scheduled maintenance course was noted in 169/276 (61%). In the episodic maintenance arm, 19/40 (48%) had successful maintenance therapy. At 5 years, the overall estimated sustained benefit was 55.7% (95% CI: 48.8 -62.6).
Maintenance therapy, either scheduled or episodic, was discontinued due to failure after a median treatment duration of 14.7 months (IQR 6.9 -31.9) in 128 patients (40%). Of those, seven patients had co-morbidity irrespective of (lack of) response that required them to stop (carcinoma or dysplasia in three, an infection in three and a cardiovascular event in one patient). Table 2 clarifies timing and reason for discontinuation in all patients at risk during follow-up. No differences were found in the Kaplan-Meier failure-free survival analyses stratified for AMC or VUMC. Figure 2 shows the failure-free survival of all patients who received maintenance therapy. In stratification analyses, patients with concomitant thiopurine therapy at start of IFX experienced significantly less failures and, if so, then later (P = 0.010). Furthermore, a diagnosis after 40 was associated with worse outcome (P = 0.009). Influence on sustained benefit from steroid use at start (P = 0.072) did not reach statistical significance, and resection prior to start (P = 0.647), and scheduled versus episodic therapy (P = 0.288) showed no statistically significant difference. Clinical response reflected by surgical interventions Figure 3 shows the number of abdominal surgical interventions per 100 follow-up years before and after initiation of IFX-treatment. The decrease from 9.63 to 8.62 interventions per 100 follow-up years was not statistically different (P = 0.356). In the subgroup of patients with scheduled maintenance therapy (n = 276), a significant decrease in surgical intervention rates was observed after start with IFX. Before start this group underwent 8.76 abdominal surgeries per 100 patient years; after start this decreased to 6.06 interventions, a reduction of 31% (95% CI: -4.82 to -0.35; P = 0.018). Subdividing this cohort in groups with and without prior resection before IFX therapy, 27 of 112 patients with prior resections required a reoperation after start with IFX (24%), predominantly right-sided colonic resection (n = 17) or small bowel (n = 6). In the group of 164 patients with no resection prior to IFX, 30 patients required resection after receiving IFX therapy (18%), in most cases right-sided colonic resection (n = 22). Hence, prior resection did not seem to confer a protective effect upon the chance of recurrent surgery. Figure 4 depicts the course of treatment during the second episode of 131 patients who received a second episode of IFX therapy. Outcome was similar to the first episode with successful remission induction in 82% of patients and successful maintenance therapy in 65%. Fifty-seven patients were considered failure in their first treatment episode. The second treatment episode turned out to be clinically beneficial in 27 of these 57 patients (47%). Outcome of the second IFX episode was not influenced by a resection, adalimumab therapy or trial medication between the first and second episode (data not shown).
Safety
Fifty-six patients (12%) discontinued the first IFX therapy episode due to adverse effects ( Figure 1) . Infusion reaction was the reason for withdrawal in 32 patients (7% of whole cohort); 5 patients stopped due to onset or worsening of arthralgia; three patients had a lupus like syndrome, two patients had a delayed type hypersensitivity; cutaneous eruptions were seen in two; general malaise in two; infection in three; neurological symptoms in two. Anaphylactic shock, oedema, abscess formation, headache, and depressive symptoms were each documented in one patient. Ten patients discontinued IFX therapy because of comorbidity. The second episode of IFX therapy was discontinued in 26 (20%) due to adverse effects ( Figure 4) . This proportion was significantly higher compared with the number of patients discontinuing the first episode because of adverse effects (20% vs. 12%; P = 0.020). Of these 26, five had also discontinued the first episode because of adverse effects.
Successful remission induction: 108
Other / no therapy: 13 Mortality Nine patients (1.9%; 0.39/100 patient years) died at a median age of 47.9 years (IQR: 40.5 -53.7). Median time between last infusion and death was 6.5 months (IQR: 3.5 -48.7), and median number of infusions was 4 (IQR: 2 -6.5). Five patients died of malignancies, 1 patient died of a myocardial infarction, one patient died of a bowel perforation and one patient died of a bilateral pneumonia. The experts estimated the relation between death and infliximab therapy of this last patient to be probably related, all other causes were estimated as possibly related. Of one patient the exact cause of death remained unknown, for she died while being abroad for a second opinion in her nation of birth.
Malignancy
Thirteen patients (2.8%; 0.57/100 patient years) developed a malignancy. These were gastrointestinal (n = 5); haematological (n = 3); respiratory (n = 2), gynaecological (n = 1) and skin (n = 2) malignancies. In 6 patients (median age 53 (IQR 35 -57)) this was diagnosed during IFX therapy, after a median of 11 (IQR 4 -23) infusions. In the remaining 7 patients, IFX had been discontinued for a median of 36 (IQR 8 -57) months after 3 (IQR 1 -12) infusions. Median age was 45 (IQR 37 -46). All malignancies were estimated to be possibly related to IFX by the experts. Five patients died, these are discussed in the paragraph on mortality. 
Discussion
With a median follow-up of almost 4.5 year in 469 CD patients, the present study is one of the two largest IFX cohorts presented to date. This study showed that clinical response to the remission induction infusions with IFX was successful in 85% of patients. Sustained clinical benefit was estimated to 55.7% at five years. Scheduled IFX therapy was associated with less need for surgery.
Compared to the large randomized trials that evaluated one-year efficacy by CDAI, global physician's assessed benefit of therapy appears much more favourable. In our cohort, maintenance therapy was considered successful in approximately 80% at 12 months (fig 2) , whilst in the two randomized studies evaluated in the Cochrane review regarding anti-TNF as maintenance therapy, response was seen in 44%-62% and remission in 33% -53% of patients at 12 months. 17 This difference can be explained by the applied criteria for response (a CDAI-drop of > 70 points) and remission (CDAI < 150), used in these intervention trials. In daily practice, global physician's assessment rather than changes in activity scores is used to decide whether a patient has a favourable response. The present study reflects this daily practice.
A number of other studies on IFX efficacy in daily practice are published, but these are limited by rather small cohorts and a short period of follow-up. [18] [19] [20] [21] Only one large single centre cohort similar to the present study has been published 22 . In this Belgian cohort, a sustained benefit of 63.4% in patients receiving maintenance therapy was reported. In their series, sustained benefit was defined as lasting control of disease during follow-up. The corresponding figure in our cohort was 61%. However, this approach does not account for the length of the period the patient had benefit of the treatment. Hence, a patient who has 4 years of therapy benefit before she/he develops an adverse reaction necessitating discontinuation in the end will be counted as a failure, while in daily clinical practise this would hardly be qualified as such. In our cohort, 13 patients failed therapy after 5 to 11 years of IFX treatment. Conversely, 11 patients in the Belgian cohort were regarded as treatment success while having a follow up time of only 3 months to one year. Conceivably, some of these would qualify as failures if follow-up had been longer. Therefore, in describing long-term results of IFX therapy, we feel emphasis should be placed on Kaplan-Meier survival estimates. The 5-year sustained benefit estimate in the Belgian cohort was 57%, which is quite similar to our findings.
Schnitzler et al. reported a significantly higher proportion of patients needing major abdominal surgery in those who were primary non-responders. 22 Since IFX is indicated for therapy refractory disease it is obvious that for primary non-responders, surgery is imminent in a number of cases. Therefore, to assess the protective effect of IFX treatment on future surgery, we judged it more appropriate to analyse only a subgroup of patients who met the following two criteria for IFX therapy: (I) they had to be on maintenance treatment, thereby reasonably filtering out those patients who were started on IFX while in fact having fibrotic disease for which they needed surgery anyway, and (II) they had to receive the superior scheduled regimen. 23 CD is a progressive disease in which longer disease duration comes with higher risk to require surgery. 24 The finding that the rate of abdominal surgery in patients on scheduled maintenance 6 therapy was in fact significantly reduced after start with maintenance IFX, corroborates the hypothesis that IFX shows promise as preventive therapy for future Crohn's related surgery. 25 This is in contrast with publications suggesting that IFX only postpones rather than prevents surgery. [26] [27] [28] It must be noted that the reduction of surgery found in this study did not apply to patients who did not have a favourable response to induction treatment. In the total cohort, no reduction was found, which is in accordance with the literature. Furthermore, due to the retrospective nature of this study no correction for all possible confounders could be performed.
In contrast to the data from Belgium, we observed a correlation between the combination of IFX with immunomodulatory drugs and a favourable therapeutic outcome. 22 This is in line with the results from the SONIC-trial, which showed that, albeit only after ≥18 weeks of follow-up, therapy was more successful when combining IFX with azathioprine in thiopurine naïve patients. 29 An additional factor impairing favourable response was higher age at diagnosis. To our knowledge, this association has not been reported before. It may either be the result of a type 1 error or a consequence of the fact that Montreal age classification truly reflects a distinct type of CD, less well responding to IFX treatment.
A similar rate of successful therapy was noted in patients retreated with IFX in a second episode. Remarkably, previous failure was not predictive for failure in later episodes, for 47% of the 57 patients who failed their first IFX episode and received a second course experienced clinical benefit from this second course. Some of the first-episode failures might be explained by improper indication, like fibrotic-type disease needing surgery instead of medical therapy. Therapeutic response might have been awaited too impatiently in some patients. It is unlikely that this accounts for all unsuccessful first episodes. Retreatment with IFX in patients previously failing on IFX may thus be worthwhile in disease refractory to other treatment modalities. Mortality was 1.9%, or 0.39/100 patient years in these series. This is comparable to the rate of 0.3/100 patient years documented by Fidder et al., and the 0.53/100 patient years reported from the TREAT registry. 30;31 One cause of death in these series was considered 'probably related' to IFX; all other known causes were judged to be possibly related to IFX.
Malignancies were found in 2.8% of patients, or 0.57/100 patient years, with higher incidences in patients aged 40-70 compared to patients aged 10-40. This was higher compared to the 0.4/100 patient years malignancy rate reported earlier. 30 The absolute percentage was comparable to other long-term studies evaluating the risk of cancer during anti TNF therapy in IBD. 32;33 It remains difficult to assess the degree of IFX involvement in pathogenesis of neoplasia in the course of IBD. Considering the pleiotropic effects of TNF, it cannot be ruled out that IFX is related with development of any neoplasia. Most patients, however, usually have immunosuppressive (co-)medication also alleged to contribute to neoplasia generation. It remains a matter of discussion but the absolute risk seems rather limited.
Compared to the literature, rate of serious infections leading to discontinuation was low. 32;34;35 More infections occurred in this series without any consequence for continuation of therapy. The true infection rate may possibly have been higher and underreported in the IBD charts.
An intrinsic shortcoming of this study is its retrospective nature. This may have affected assessment of efficacy and especially adverse events. Disease activity scales were not routinely documented and not all patient data could be retrieved. With regard to adverse events, full documentation was lacking, and underreporting cannot be ruled out. Infusion reactions were only consistently documented when severe and leading to discontinuation of therapy.
In conclusion, the present study showed that long-term real life treatment with IFX for CD has longstanding sustained benefit in more than half of patients. Long-term use of IFX is safe and prevents surgery in patients on scheduled maintenance therapy. Previous therapeutic failure on IFX should not preclude its future use in individual patients. 
